Natural Chronic Pain Treatment – and More!
Cartigenix is one of the most important supplements ever created. Not only does it dramatically improve symptoms of osteoarthritis without side effects, it actually repairs the structure of joints! With the biochemical changes it produces in the body, it is reasonable to expect it to slow, delay, prevent, or even reverse the other degenerative diseases of aging!
In a plecbo-controlled study of 1236 subjects with osteoarthritis, 85% of subjects had moderate to excellent pain relief with Cartigenix.
Cartigenix is the wildly successful result of a long mission to create a product to actually improve joint health, not just reduce symptoms. A team of scientists spent decades studying the biology of degenerative joint disease in order to come up with this natural solution comprised of new extracts of two natural plants: boswellia serrata and wild celery seed.
While there are other natural products that safely reduce inflammation and associated pain, none do what Cartigenix has been demonstrated to do. What about drugs? Conventional medicine primarily uses non-steroidal anti-inflammatory drugs (NSAIDs) and pain killers to treat osteoarthritis. An estimated 107,000 hospitalizations and 16,500 deaths annually are attributed to NSAID use, primarily from gastrointestinal bleeding and cardiovascular complication. Longterm use of NSAIDs as chronic pain treatment is problematic. These drugs damage the gastrointestinal lining, leading to leaky gut syndrome, which is a major contributor to systemic inflammation, including osteoarthritis – the very condition they are being used to treat! While NSAIDs can give symptomatic relief, they interfere with healing and may actually accelerate joint breakdown!
Cartigenix has been proven to safely reduce pain, swelling and stiffness, and increase walking ability in subjects with osteoarthritis of the knee. It has been found to reduce a variety of inflammatory and tissue degrading biochemicals, while increasing regenerative biochemicals. To me, the most impressive finding is probably the structural improvement evidenced by way of X-rays before and 3 months after Cartigenix usage.
In people with osteoarthritis of the knee, Cartigenix has been demonstrated to:
- Reduce pain and stiffness
- Reduce need for pain medication
- Increase mobility
- Decrease inflammatory chemicals
- Reduce biochemicals of joint breakdown
- Increase biochemicals of joint repair
- Documented increases in knee joint space on X-ray
- Reduce gastrointestinal symptoms
- Reduce fatigue
The specialized celery seed extract developed for later inclusion in Cartigenix is standardized for 3 newly identified constituents of importance and possesses notable analgesic and anti-inflammatory properties. Initially, it was marketed as a standalone product and was sold as a prescription pain medication in India. Several clinical studies involving people with arthritis have demonstrated that this unique celery seed extract is effective in reducing pain and improving joint function. It has shown comparable efficacy to common NSAIDs like aspirin and ibuprofen in suppressing arthritis symptoms and acts as an analgesic in experimental models. Additionally, celery seed extract has protective effects against gastric irritation caused by NSAIDs.
Over the course of years, and with the help of artificial intelligence, seven analytical chemists identified 10 important new bioactive constituents of boswellia, which is an ancient anti-inflammatory remedy and chronic pain treatment, referred to as Frankincense. One of these substances, serratol, was found to have tissue regenerative properties. Cartigenix has been shown in experimental models to protect against and reduce gastric irritation and ulcer formation, while also promoting the healing of existing ulcers. This protective effect is attributed to its ability to enhance angiogenesis and increase expression of growth factors like VEGF, along with reducing inflammatory mediators, which collectively support gastric mucosal repair and ulcer recovery. Perhaps some of its ability to improve joint health is mediated through the gut-joint axis. This is in stark contrast to NSAIDs, which cause gastrointestinal mucosal injury, leaky gut syndrome, and ulcerations.
The first human clinical study on the celery seed-boswellia combination that is found in Cartigenix was published in 2022. All 1236 subjects with osteoarthritis received Cartigenix daily for 3 months. Compared to baseline, patients showed large and statistically significant improvements: WOMAC scores fell from a mean of ~62.6 to ~17.2. The WOMAC score (Western Ontario and McMaster Universities Osteoarthritis Index) is a widely used questionnaire for assessing pain, stiffness, and physical function in people with osteoarthritis with higher scores indicating worse symptoms and functional limitations. Pain on the Visual Analogue Scale (VAS) dropped from ~8.07 to ~1.78. The Visual Analogue Scale (VAS) is a straightforward tool for measuring pain intensity. It consists of a 10 cm horizontal line with endpoints labeled “no pain” and “worst pain imaginable.” Patients indicate their pain level by marking a point along the line, which is then measured from the “no pain” end to provide a pain score from 0 to 10, with higher scores representing greater pain. The subjects were also evaluated with the Total European Quality of Life–5 Dimensions (EQ-5D) score, which is a standardized questionnaire designed to assess health-related quality of life through five key dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Additionally, the EQ-5D includes a visual analogue scale (VAS) where individuals rate their overall health on a scale ranging from the worst to the best health they can imagine, offering a quantitative measure of their perceived well-being. Quality of life as assed by th EQ‑5D questionnaire rose by 78%. Importantly, there were no major adverse reactions reported, suggesting the combination was well tolerated.
Another study was published on Cartigenix in 2024. In a three month study of 394 people with osteoarthritis of the knee, Cartigenix was given in addition to what the subjects were already using for their condition. Again, Cartigenix was found to significantly reduce pain and improve physical function. Importantly, NSAID usage among patients decreased sharply—from about 70% at baseline to ~32% at the end of the study
The third study on Cartigenix, which was published in 2025, was randomized, double-blind, placebo controlled, and very ambitious. It was performed on 62 subjects with knee osteoarthritis. In addition to the measures of symptoms and function it added before and after X-rays, and serial measures of biomarkers of inflammation, cartilage degradation and cartilage regeneration. Subjects taking Cartigenix experienced reductions in pain, stiffness, and swelling, which were noted starting after the first week with continued improvement over time. By the end of the three month study, people taking Cartigenix had roughly a 65% reduction in pain (64.0% reduction in total WOMAC pain-stiffness score and 67.7% reduction in VAS pain score). While subjects taking placebo were not moving around any better, those taking Cartigenix had a tremendous improvement: they increased distance walked in a six minute timed test by 57.4%! Inflammation reduction expressed as an average across the seven biomarkers (IL-1, IL-6, TNF-a, IL-17, ESR, and Hs CRP) was 40%. If you get a somewhat thorough yearly physical, your Hs CRP is one of the tests done. Hs CRP, which decreased 56% with Cartigenix, is an independent cardiovascular risk factor; and it is much more than that. In fact, these inflammatory chemicals are major mediators of chronic conditions, including autoimmune disease, cancer, metabolic syndrome, diabetes, osteoporosis, sarcopenia, neurodegenerative disease, and more. We naturally get greater expression of inflammatory genes with age, which has led to the term “inflammaging”. Inflammation not only contributes to pain, joint breakdown, and degenerative diseases of aging but also to fatigue, mood disorders, and much more. So, if you take Cartigenix as safe chronic pain treatment, don’t be surprised if there are other health benefits! Cartigenix was found to both slow cartilage breakdown and speed cartilage repair; there was an average reduction in cartilage degeneration biomarkers of 33% and an increase of 46% in cartilage regeneration biomarkers. Incredibly, comparing X-rays at the start of the study to hose taken after 90 days of Cartigenix usage showed increase in joint space, indicating the presence of more cartilage. Subjects in both groups were allowed to ask to take Celecoxib, an NSAID, if they were experiencing too much pain at any point during the study. By the end of the study, 80% of subjects taking placebo were taking Celecoxib, while only 10% of the Cartigenix group was. Thirty days after completion of the study (subjects off of placebo and Cartigenix), 100% of the subjects given placebo were back on pain medication, while only 13% of subjects that had been on Cartigenix were on pain medication. One month without taking any Cartigenix and these subjects were still feeling good. I attribute that to restoration of healthy joint structure.
Subjects taking Cartigenix experienced no gastrointestinal side effects. In fact, all patients using Cartigenix who had gastric issues at the start of the study reported significant reductions in heartburn, gastric discomfort, and epigastric pain, with 100% of these patients showing improvement.
What is possibly most incredible about this study may not be obvious at first look. Data analyzed at the end of the study showed the Cartigenix group outperforming placebo in every area: pain and stiffness, walking ability, biochemical measures of inflammation, degeneration, and repair, as well as changes in joint appearance on X-ray. The placebo group showed only minor improvements in pain (7.5% reduction in VAS) and function (4–7% on WOMAC scores), whereas the treatment (Cartigenix) group , had pain reduction over 60% and functional scores improving by more than 50%. Here’s the amazing thing: Since 80% of people taking placebo were also using the prescription pain medication Celecoxib, but only 10% of the Cartigenix group was taking Celecoxib (90% of the Cartigenix group was taking only Cartigenix), this study actually wound up effectively comparing Cartigenix to the prescription NSAID Celecoxib! Cartigenix was clearly far superior.
Cartigenix reduces inflammation and biochemicals that degrade cartilage, while stimulating production of biochemicals that repair cartilage. The effects are so dramatic that return of joint cartilage is evidenced by increased (more normal) joint space on X-ray after 90 days!
Unlike NSAIDs, Cartigenix doesn’t cause ulcers, kidney damage, cardiovascular events, or other serious conditions, to the point of increased risk of death. If Cartigenix is added to NSAID treatment, it would be expected to produce further improvement in joint comfort while protecting against ulceration.
It is reasonable to expect Cartigenix to have a positive effect on the other degenerative conditions of aging. Not only are inflammatory mediators and tissue-degrading biochemicals involved in other conditions but the increased activity afforded by improvement in osteoarthritis symptoms has positive biological effects. Joint degeneration usually begins in our 20s. Ninety percent of people over age 50 have MRI evidence of joint degeneration. Don’t wait for your joints to become painful and stiff – take Cartigenix as a preventive at 1 pill per day. Think of it as a multivitamin for your joints – and guardian of a healthy future. A therapeutic dose (used in studies) as chronic pain treatment is 2 pills per day.
Order Cartigenix. If sold out, try here: Cartigenix.